Pfizer (NYSE: PFE) revenue
Pfizer reported revenue of $62,579m for fiscal 2025, 1.6% less than in fiscal 2024 ($63,627m). Since fiscal 2016 its revenue has grown by 18.5%, an average growth of 1.9% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $62,579m | −1.6% | $10,191m | 16.3% |
| 2024 | $63,627m | +6.8% | $11,114m | 17.5% |
| 2023 | $59,553m | −41.1% | $3,267m | 5.5% |
| 2022 | $101,175m | +24.5% | $35,967m | 35.5% |
| 2021 | $81,288m | +95.2% | $25,602m | 31.5% |
| 2020 | $41,651m | +1.8% | $8,485m | 20.4% |
| 2019 | $40,905m | +0.2% | $12,894m | 31.5% |
| 2018 | $40,825m | −22.3% | $4,910m | 12.0% |
| 2017 | $52,546m | −0.5% | $13,575m | 25.8% |
| 2016 | $52,824m | — | $9,537m | 18.1% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Pfizer
- How much revenue did Pfizer make in fiscal 2025?
- Pfizer reported revenue of $62,579m for fiscal 2025, compared with $63,627m in fiscal 2024.
- How much has the revenue of Pfizer grown?
- Between fiscal 2016 and fiscal 2025 it went from $52,824m to $62,579m: 18.5% more, an average growth of 1.9% a year.
- What was the best year for revenue at Pfizer?
- Of its last 10 fiscal years, fiscal 2022, with $101,175m.
- Where do the figures for Pfizer come from?
- From the annual report (Form 10-K) that Pfizer files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Pfizer files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Pfizer: the Pfizer page · annual accounts · net income · insider transactions.
Dividend per share of Pfizer by fiscal year, with the filing behind every figure: Pfizer dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.